Mrinalini Dey DrMiniDey
1 year 8 months ago
How long before starting MTX should pts receive PCV13 vaccine?
➡️In RA, PCV13 vaccine given 1 month before starting MTX led to significantly higher immunological response at 1 month compared to pts vaccinated on MTX
⏩Vaccinate pts before starting MTX
Ab2676 #ACR24 @RheumNow
Akhil Sood MD AkhilSoodMD
1 year 8 months ago
Abstract 2681: #SDOH factors & SLE risk:
- Low income (AOR=2.779).
- By race/ethnicity NHB (AOR=2.429), Hispanic (AOR=1.616).
Behavioral: Psych distress (AOR=2.127), no exercise (AOR=1.677).
Access: Medicaid (AOR=2.540), transport barriers (AOR=20.394).
@RheumNow #ACR24
Antoni Chan MD (Prof) synovialjoints
1 year 8 months ago
For daily recaps, content and updates from #ACR24 head to https://t.co/eL0bMhnFiu @RheumNow with input from colleagues in the faculty
@synovialjoints
@bella_mehta
@ericdeinmd
@AkhilSoodMD.
@DrMiniDey
@CaoilfhionnMD
@ebrhuem
@rheumarampa
@Dr_Brian_MD
@AdelaCastro222
@JihaRheum… https://t.co/a3FQjGokhn https://t.co/1g3Fi01HWG
Janet Pope Janetbirdope
1 year 8 months ago
#Ianalumab
300 mg sc q monthly
B cell depleted and changes BAFF signalling
👇⬇️IFN
May be promising in #lupus #SLE
+data in primary #Sjogrens
ACR24 @RheumNow @ACRheum
Abst#2425
Needs Phase3
➡️I suspect safer than CAR T and Bispecific T cell engagers but
? ⬇️efficacy
Janet Pope Janetbirdope
1 year 8 months ago
ACR24 take homes
➡️#Inflammatory #myositis
#Upadacitinib improved MDA5 ILD
#Baricitinib 4mg/d good in myositis delayed start #RCT
#Tofacitinb ➡️help for skin, calcinosis, rash in case series
➡️RCT ongoing
JAKi is ‘jacked’ in muscles 💪🏿
#ACR24 @RheumNow @ACRheum
1731 0348
Janet Pope Janetbirdope
1 year 8 months ago
Biggest absence award at #ACR24 @ACRheum @RheumNow
🥇
Absence of discussion on
👇
#Oral #Surveillance
Except for maybe
Monitoring for mouth ulcers and cancers
issues are not resolved but we are comfortable with ambiguity!
Dr. John Cush RheumNow
1 year 8 months ago
Taking CAR-T for a Test Drive
What is CAR-T? How can you get a healthy dose of it at #ACR24? And what does it mean for the future? Read on to find out!
https://t.co/TnNHzWQndp https://t.co/qWgwjiEdLF
Different factors are known to influence disease characteristics and outcomes in psoriatic arthritis (PsA). Recently, there is new evidence that sex-related differences play a role not only in disease manifestations but also in efficacy and safety of treatments as well as outcomes and prognosis.
Dr. John Cush RheumNow
1 year 8 months ago
Are Emulation Trials a Fantasy?
Are these ‘trials’ helpful, despite the biases that occur with observational data, or do they truly mimic the results of randomized controlled trials (RCTs)?
https://t.co/x6NogGQksW https://t.co/f8o8N55tlJ
Dr. John Cush RheumNow
1 year 8 months ago
axSpA: Moving the needle in time to diagnosis
The journey to axial spondyloarthritis (axSpA) diagnosis is often prolonged and challenging. Understanding the factors contributing to the delays is important to improve the clinical, psychological, social and economic outcomes.… https://t.co/wnwtj8jj0q https://t.co/Pds2uxVfJV
